Multiple Sclerosis: Immunopathology and Treatment Update
Open accessThe DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year. Herein, we go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments. We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 3×
“The M2 macrophage phenotype of mice (F4/80+CD11c−CD301+Arg1+CD206+) and humans (CD163+CD206+) is induced in the presence of IL-4, IL-10, IL-13 and Arg1 that blocks iNOS activity [51].”
BackgroundNew Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581 · cited 1×
“Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator, which acts as a super agonist of S1P receptor causing receptor internalization and leading to reduced infiltration of potentially auto-reactive lymphocytes into the CNS, and as such, they remain localized in the lymph nodes [132] [133] [134] .”
BackgroundB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
MR1 presents microbial vitamin B metabolites to MAIT cells
Kjer-Nielsen, L., Patel, O., Corbett, A. J., Le Nours, J., Meehan, B., Liu, L., Bhati, M., Chen, Z., Kostenko, L., Reantragoon, R., et al. (2012) · Nature · doi:10.1038/nature11605 · Cited by 1,351 · cited 1×
“The MHC class I-like molecule, MRI, presents microbial antigens and vitamin B metabolites to MAIT cells, leading to their activation [39,40].”
BackgroundA Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205 · cited 5×
“Based on Phase III human clinical trials in patients with RRMS (TRANSFORMS, FREEDOMS and FREEDOMS II), fingolimod was more effective compared to first line treatment IFNβ-1a and placebo, in reducing the frequency of flare-ups (clinical exacerbations), disability progression, MRI outcome measures, including brain volum…”
BackgroundInfluentialColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198 · cited 5×
“Based on Phase III human clinical trials in patients with RRMS (TRANSFORMS, FREEDOMS and FREEDOMS II), fingolimod was more effective compared to first line treatment IFNβ-1a and placebo, in reducing the frequency of flare-ups (clinical exacerbations), disability progression, MRI outcome measures, including brain volum…”
BackgroundInfluentialGirard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M., & Fugger, L. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070690 · Cited by 1,187
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System
Steinman, M. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81107-1 · Cited by 903
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Kohm, A. P., Carpentier, P. A., Anger, H. A., & Miller, S. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4712 · Cited by 782
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Blood-brain barrier disruption in multiple sclerosis
Minagar, A., & Alexander, J. S. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms965oa · Cited by 638
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Pathogen recognition and development of particulate vaccines: Does size matter?
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & Plebanski, M. (2006) · Methods · doi:10.1016/j.ymeth.2006.05.016 · Cited by 602
Self-citationChoi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
McGeachy, M. J., Stephens, L. A., & Anderton, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3025 · Cited by 556
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Comi, G., Kappos, L., Oger, J., et al. (2000) · Nature Medicine · doi:10.1038/80525 · Cited by 512
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Vogel, D. Y., Vereyken, E. J., Glim, J. E., Heijnen, P. D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C. E., van Horssen, J., & Dijkstra, C. D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-35 · Cited by 479 · cited 1×
“However, a distinction of M1 vs M2 macrophages in human brain tissues is not so clear, with both M1 macrophages and an intermediate subtype (M1/M2, CD40+CD206+) being present [53].”
BackgroundType II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447 · cited 1×
“In addition, induction of Treg cells by estradiol or by monocytes under glatiramer acetate treatment reduced clinical signs of MOG-EAE [46,47].”
BackgroundWolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C., Brochet, B., Berry, I., Rolland, Y., Froment, J. C., et al. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.2.112 · Cited by 425
Jahng, A., Maricic, I., Aguilera, C., Cardell, S., Halder, R. C., & Kumar, V. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031389 · Cited by 409
Zhang, X. (2004) · International Immunology · doi:10.1093/intimm/dxh029 · Cited by 363
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
O’Connor, P. W., Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P. A., Confavreux, C., Paty, D. W., Stewart, J. A., & Scheyer, R. (2006) · Neurology · doi:10.1212/01.wnl.0000203121.04509.31 · Cited by 358
Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study
Yamout, B., Hourani, R., Salti, H., Barada, W., El-Hajj, T., Al-Kutoubi, A., Herlopian, A., Baz, E. K., Mahfouz, R., Khalil-Hamdan, R., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.07.013 · Cited by 356
Vermersch, P., Czlonkowska, A., Grimaldi, L. M., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benamor, M., Bauer, D., Truffinet, P., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507821 · Cited by 354
Evidence for genetic basis of multiple sclerosis
Sadovnick, A. D., the Canadian Collaborative Study Group, Dyment, D. A., Ebers, G. C., & Risch, N. J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90807-7 · Cited by 351
van Hamburg, J. P., Asmawidjaja, P. S., Davelaar, N., Mus, A. M. C., Colin, E. M., Hazes, J. M. W., Dolhain, R. J. E. M., & Lubberts, E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30093 · Cited by 341
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles
Kaer, L. V. (2005) · Nature Reviews Immunology · doi:10.1038/nri1531 · Cited by 299
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000125 · Cited by 278
Bennett, J., Basivireddy, J., Kollar, A., Biron, K. E., Reickmann, P., Jefferies, W. A., & McQuaid, S. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.011 · Cited by 265
Shirani, A., Zhao, Y., Karim, M. E., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Gustafson, P., Petkau, J., & Tremlett, H. (2012) · JAMA · doi:10.1001/jama.2012.7625 · Cited by 263
Karanikas, V, Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V, Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119825 · Cited by 263
Self-citationImmunopathogenesis and immunotherapy of multiple sclerosis
Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., & Hartung, H.-P. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0154 · Cited by 254
Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
Goodin, D. S., Reder, A. T., Ebers, G. C., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., DeSimone, T. M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535cf6 · Cited by 249
Mechanisms of action of glatiramer acetate in multiple sclerosis
Neuhaus, O., Farina, C., Wekerle, H., & Hohlfeld, R. (2001) · Neurology · doi:10.1212/wnl.56.6.702 · Cited by 248
The role of regulatory T cells in multiple sclerosis
Zozulya, A. L., & Wiendl, H. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0832 · Cited by 240
The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases
Tabarkiewicz, J., Pogoda, K., Karczmarczyk, A., Pozarowski, P., & Giannopoulos, K. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0344-z · Cited by 238
Liu, C., Li, Y., Yu, J., Feng, L., Hou, S., Liu, Y., Guo, M., Xie, Y., Meng, J., Zhang, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054841 · Cited by 233
Effects of dimethyl fumarate on neuroprotection and immunomodulation
Albrecht, P., Bouchachia, I., Goebels, N., Henke, N., Hofstetter, H. H., Issberner, A., Kovacs, Z., Lewerenz, J., Lisak, D., Maher, P., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-163 · Cited by 227
The evidence for a role of B cells in multiple sclerosis
Disanto, G., Morahan, J. M., Barnett, M. H., Giovannoni, G., & Ramagopalan, S. V. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f6f0 · Cited by 220
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel, J., Antel, S., Caramanos, Z., Arnold, D. L., & Kuhlmann, T. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0953-0 · Cited by 215
Autologous haematopoietic stem-cell transplantation in multiple sclerosis
Mancardi, G., & Saccardi, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70138-8 · Cited by 206
Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
Citterio, A., La Mantia, L., Ciucci, G., Candelise, L., Brusaferri, F., Midgard, R., & Filippini, G. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001331 · Cited by 204
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203 · cited 1×
“anti-CD28 monoclonal antibody in Lewis rats results in Treg cell expansion and reduction in EAE disease severity [48].”
BackgroundAbrahamsson, S. V., Angelini, D. F., Dubinsky, A. N., Morel, E., Oh, U., Jones, J. L., Carassiti, D., Reynolds, R., Salvetti, M., Calabresi, P. A., et al. (2013) · Brain · doi:10.1093/brain/awt182 · Cited by 194
Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis
Miyazaki, Y., Miyake, S., Chiba, A., Lantz, O., & Yamamura, T. (2011) · International Immunology · doi:10.1093/intimm/dxr047 · Cited by 193
Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.
Apostolopoulos, V, Pietersz, G. A., Loveland, B. E., Sandrin, M. S., & McKenzie, I. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10128 · Cited by 189
Self-citationThe complex immunological and inflammatory network of adipose tissue in obesity
Apostolopoulos, V., de Courten, M. P. J., Stojanovska, L., Blatch, G. L., Tangalakis, K., & de Courten, B. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500272 · Cited by 187
Self-citationPeferoen, L. A. N., Vogel, D. Y. S., Ummenthum, K., Breur, M., Heijnen, P. D. A. M., Gerritsen, W. H., Peferoen-Baert, R. M. B., van der Valk, P., Dijkstra, C. D., & Amor, S. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000149 · Cited by 178 · cited 1×
“In MS brain lesions however, like macrophages, an intermediate microglia phenotype is present expressing CD40, CD74, CD86 and CCL22 but not CD206 markers [54].”
Wu, Q., Wang, Q., Mao, G., Dowling, C. A., Lundy, S. K., & Mao-Draayer, Y. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601532 · Cited by 177
Apostolopoulos, V., Pietersz, G. A., Tsibanis, A., Tsikkinis, A., Drakaki, H., Loveland, B. E., Piddlesden, S. J., Plebanski, M., Pouniotis, D. S., Alexis, M. N., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1505 · Cited by 173
Self-citationMannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma
Loveland, B. E., Zhao, A., White, S., Gan, H., Hamilton, K., Xing, P.-X., Pietersz, G. A., Apostolopoulos, V., Vaughan, H., Karanikas, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1574 · Cited by 172
Self-citationAutologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis
Sormani, M. P., Muraro, P. A., Schiavetti, I., Signori, A., Laroni, A., Saccardi, R., & Mancardi, G. L. (2017) · Neurology · doi:10.1212/wnl.0000000000003987 · Cited by 167
Bar-Or, A., Vollmer, T., Antel, J., Arnold, D. L., Bodner, C. A., Campagnolo, D., Gianettoni, J., Jalili, F., Kachuck, N., Lapierre, Y., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.10.nct70002 · Cited by 166
Cappellano, G., Woldetsadik, A. D., Orilieri, E., Shivakumar, Y., Rizzi, M., Carniato, F., Gigliotti, C. L., Boggio, E. M., Clemente, N., Comi, C., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.016 · Cited by 165
Llufriu, S., Sepúlveda, M., Blanco, Y., Marín, P., Moreno, B., Berenguer, J., Gabilondo, I., Martínez-Heras, E., Sola-Valls, N., Arnaiz, J.-A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113936 · Cited by 165
Round and Round we Go: Cyclic Peptides in Disease
Matsoukas, J., Apostolopoulos, V., Lazoura, E., Deraos, G., Matsoukas, M.-T., Katsara, M., Tselios, T., & Deraos, S. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777935113 · Cited by 163
Self-citationTh2 bias of CD4+ NKT cells derived from multiple sclerosis in remission
Araki, M. (2003) · International Immunology · doi:10.1093/intimm/dxg029 · Cited by 162
Multiple sclerosis: New insights and trends
Koriem, K. M. M. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.009 · Cited by 150
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G. B., Tortorella, C., Simone, I. L., Patti, F., Ghezzi, A., Zipoli, V., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21757 · Cited by 148
Macrophages in Multiple Sclerosis
Brück, W., Sommermeier, N., Bergmann, M., Zettl, U., Goebel, H. H., Kretzschmar, H. A., & Lassmann, H. (1996) · Immunobiology · doi:10.1016/s0171-2985(96)80024-6 · Cited by 139 · cited 1×
“In fact, in active demyelinating and early re-myelinating lesions, macrophages are highly present compared to inactive, demyelinated or late re-myelinated lesions [52].”
BackgroundFumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Moharregh-Khiabani, D., Linker, R., Gold, R., & Stangel, M. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602788 · Cited by 139
Mars, L. T., Laloux, V., Goude, K., Desbois, S., Saoudi, A., Van Kaer, L., Lassmann, H., Herbelin, A., Lehuen, A., & Liblau, R. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6007 · Cited by 138
Wekerle, H. (2017) · Autoimmunity · doi:10.1080/08916934.2017.1281914 · Cited by 131
The Role of Mucosal Associated Invariant T Cells in Antimicrobial Immunity
Napier, R. J., Adams, E. J., Gold, M. C., & Lewinsohn, D. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00344 · Cited by 129
Koch, M. W., Mostert, J. P., de Vries, J. J., & De Keyser, J. (2007) · Neurology · doi:10.1212/01.wnl.0000261131.23708.1c · Cited by 128
Interleukin-27 in T Cell Immunity
Iwasaki, Y., Fujio, K., Okamura, T., & Yamamoto, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022851 · Cited by 127
Haas, J., Korporal, M., Balint, B., Fritzsching, B., Schwarz, A., & Wildemann, B. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.06.011 · Cited by 119
Th9 cells and IL-9 in autoimmune disorders: Pathogenesis and therapeutic potentials
Deng, Y., Wang, Z., Chang, C., Lu, L., Lau, C. S., & Lu, Q. (2016) · Human Immunology · doi:10.1016/j.humimm.2016.12.010 · Cited by 117
Korn, T., Magnus, T., Toyka, K. V., & Jung, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504308 · Cited by 113
Huang, Y.-M., Xiao, B., Özenci, V., Kouwenhoven, M. C. M., Teleshova, N., Fredrikson, S., & Link, H. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00106-x · Cited by 101
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β
Rolla, S., Bardina, V., Mercanti, S. F. D., Quaglino, P., Palma, R. D., Gned, D., Brusa, D., Durelli, L., Novelli, F., & Clerico, M. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.5a0813-463rr · Cited by 101
Vassilaros, S. D., Tsibanis, A., Tsikkinis, A., Pietersz, G. A., McKenzie, I. F. C., & Apostolopoulos, V. (2013) · Immunotherapy · doi:10.2217/imt.13.126 · Cited by 99
Self-citationXiang, S. D., Selomulya, C., Ho, J., Apostolopoulos, V., & Plebanski, M. (2010) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.88 · Cited by 93
Self-citationBleeker, W. K., Munk, M. E., Mackus, W. J. M., van den Brakel, J. H. N., Pluyter, M., Glennie, M. J., van de Winkel, J. G. J., & Parren, P. W. H. I. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06916.x · Cited by 91
Kallaur, A. P., Lopes, J. M., Oliveira, S. R., Simão, A. N. C., Reiche, E. M. V., de Almeida, E. R. D., Morimoto, H. K., de Pereira, W. L. C. J., Alfieri, D. F., Borelli, S. D., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9443-4 · Cited by 87
Havrdová, E., Zivadinov, R., Krásenský, J., Dwyer, M. G., Nováková, I., Doležal, O., Tichá, V., Dušek, L., Houžvičková, E., Cox, J., et al. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509105229 · Cited by 84
Promoting Remyelination in Multiple Sclerosis—Recent Advances
Jolanda Münzel, E., & Williams, A. (2013) · Drugs · doi:10.1007/s40265-013-0146-8 · Cited by 83
Thalamus pathology in multiple sclerosis: from biology to clinical application
Kipp, M., Wagenknecht, N., Beyer, C., Samer, S., Wuerfel, J. T., & Nikoubashman, O. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1787-9 · Cited by 82
Multiple sclerosis: Therapeutic applications of advancing drug delivery systems
Dolati, S., Babaloo, Z., Jadidi‐Niaragh, F., Ayromlou, H., Sadreddini, S., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.010 · Cited by 80
Dandekar, A. A., Wu, G. F., Pewe, L., & Perlman, S. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6115-6120.2001 · Cited by 78
Tselios, T. V., Apostolopoulos, V., Daliani, I., Deraos, S., Grdadolnik, S. G., Mavromoustakos, T., Melachrinou, M., Thymianou, S. P., Probert, L., Mouzaki, Α., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102147 · Cited by 77
Self-citationTime trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades
Grytten, N., Torkildsen, Ø., & Myhr, K. ‐. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12428 · Cited by 76
Sénécal, V., Deblois, G., Beauseigle, D., Schneider, R., Brandenburg, J., Newcombe, J., Moore, C. S., Prat, A., Antel, J. P., & Arbour, N. (2015) · Glia · doi:10.1002/glia.22948 · Cited by 74
Sheremata, W. A., Minagar, A., Alexander, J. S., & Vollmer, T. L. (2005) · CNS Drugs · doi:10.2165/00023210-200519110-00002 · Cited by 73
Myeloid Derived Suppressor Cells and Their Role in Diseases
Kong, Y., Fuchsberger, M., Xiang, S. D., Apostolopoulos, V., & Plebanski, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320110006 · Cited by 72
Self-citationDressel, A., Chin, J., Sette, A., Gausling, R., Höllsberg, P., & Hafler, D. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4943 · Cited by 71
Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis
Volpe, E., Battistini, L., & Borsellino, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/475158 · Cited by 70
Antibodies in multiple sclerosis oligoclonal bands target debris
Winger, R. C., & Zamvil, S. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609246113 · Cited by 57
Goodin, D. S., Ebers, G. C., Cutter, G., Cook, S. D., O'Donnell, T., Reder, A. T., Kremenchutzky, M., Oger, J., Rametta, M., Beckmann, K., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001972 · Cited by 56
Matejuk, A., Bakke, A. C., Hopke, C., Dwyer, J. M., Vandenbark, A. A., & Offner, H. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20145 · Cited by 54
Dai, H., Ćirić, B., Zhang, G., & Rostami, A. M. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.01.005 · Cited by 53
Myeloid‐derived suppressor cells mediate tolerance induction in autoimmune disease
Wegner, A., Verhagen, J., & Wraith, D. C. (2017) · Immunology · doi:10.1111/imm.12718 · Cited by 51
Gigli, G., Caielli, S., Cutuli, D., & Falcone, M. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02655.x · Cited by 50
Lycke, J. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615605429 · Cited by 49
Muls, N., Nasr, Z., Dang, H. A., Sindic, C., & Pesch, V. V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173780 · Cited by 49
Palmer, A. M. (2010) · PubMed · Cited by 47
Prostaglandins in pathogenesis and treatment of multiple sclerosis
Mirshafiey, A., & Jadidi‐Niaragh, F. (2010) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923971003667627 · Cited by 47
The good, the bad and the ugly: how altered peptide ligands modulate immunity
Κατσάρα, Μ., Minigo, G., Plebanski, M., & Apostolopoulos, V. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802494501 · Cited by 46
Self-citationRieckmann, P. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1511-z · Cited by 45
Tseveleki, V., Tselios, T. V., Kanistras, I., Koutsoni, O. S., Καραμίτα, Μ., Vamvakas, S. M., Apostolopoulos, V., Dotsika, E., Matsoukas, J., Lassmann, H., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.10.019 · Cited by 44
Self-citationΚατσάρα, Μ., Yuriev, E., Ramsland, P. A., Tselios, T. V., Deraos, G., Lourbopoulos, A. I., Grigoriadis, N., Matsoukas, J., & Apostolopoulos, V. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03137.x · Cited by 44
Self-citationΚατσάρα, Μ., Deraos, G., Tselios, T. V., Matsoukas, M., Friligou, I., Matsoukas, J., & Apostolopoulos, V. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801250v · Cited by 43
Self-citationDendritic cell immunotherapy: clinical outcomes
Apostolopoulos, V., Pietersz, G. A., Tsibanis, A., Tsikkinis, A., Stojanovska, L., McKenzie, I. F. C., & Vassilaros, S. D. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.14 · Cited by 43
Self-citationCorticosteroids or acth for acute exacerbations in multiple sclerosis
Filippini, G., Brusaferri, F., Citterio, A., Ciucci, G., Midgar, R., Sibley, W. A., & Candelise, L. (2000) · Neurological Sciences · Cited by 43
Huang, B., Wang, Q., Song, S., Wu, Y. J., K., Y., Zhang, L. L., Chen, J. Y., Wu, H., Jiang, L., & Wei, W. (2012) · Inflammation Research · doi:10.1007/s00011-012-0520-0 · Cited by 42
Experimental models of neuroprotection relevant to multiple sclerosis
Yong, V. W., Giuliani, F., Xue, M., Bar‐Or, A., & Metz, L. M. (2007) · Neurology · doi:10.1212/01.wnl.0000275230.20635.72 · Cited by 42
Kaer, L. V., Wu, L., & Parekh, V. V. (2015) · Immunology · doi:10.1111/imm.12485 · Cited by 40
Towards immunotherapeutic drugs and vaccines against multiple sclerosis
Κατσάρα, Μ., Matsoukas, J., Deraos, G., & Apostolopoulos, V. (2008) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2008.00444.x · Cited by 38
Self-citationA double mutation of MBP83–99 peptide induces IL-4 responses and antagonizes IFN-γ responses
Κατσάρα, Μ., Yuriev, E., Ramsland, P. A., Deraos, G., Tselios, T. V., Matsoukas, J., & Apostolopoulos, V. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.013 · Cited by 37
Self-citationLong-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells
Ragheb, S., Abramczyk, S., Lisak, D., & Lisak, R. P. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700108 · Cited by 37
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis
Bianchini, E., Biasi, S. D., Simone, A. M., Ferraro, D., Sola, P., Cossarizza, A., & Pinti, M. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.01.009 · Cited by 37
Emerging immunopharmacological targets in multiple sclerosis
Farjam, M., Zhang, G., Ćirić, B., & Rostami, A. M. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.09.346 · Cited by 35
Rommer, P. S., & Stüve, O. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0233-x · Cited by 33
Salehi, Z., Doosti, R., Beheshti, M., Janzamin, E., Sahraian, M. A., & Izad, M. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159565 · Cited by 31
Al‐Ghobashy, M. A., ElMeshad, A. N., Abdelsalam, R. M., Nooh, M. M., Al‐Shorbagy, M. Y., & Laible, G. (2017) · Scientific Reports · doi:10.1038/srep46468 · Cited by 30
Immunological treatment of multiple sclerosis
Diebold, M., & Derfuss, T. J. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.04.016 · Cited by 30
Inglese, M., & Petracca, M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.040 · Cited by 29
Perera, C. J., Duffy, S. S., Lees, J. G., Kim, C. F., Cameron, B., Apostolopoulos, V., & Moalem‐Taylor, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0253-4 · Cited by 26
Self-citationEckstein, C. P., & Bhatti, M. T. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.12.001 · Cited by 24
New pieces in the puzzle: How does interferon‐β really work in multiple sclerosis?
Mitsdoerffer, M., & Kuchroo, V. K. (2009) · Annals of Neurology · doi:10.1002/ana.21722 · Cited by 22
Evolution of MS lesions to black holes under DNA vaccine treatment
Papadopoulou, A., von Felten, S., Traud, S., Rahman, A., Quan, J. M., King, R., Garren, H., Steinman, L., Cutter, G., Kappos, L., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6361-x · Cited by 19
Diagnostik der Multiplen Sklerose 2010 Revision der McDonald-Kriterien
Klotz, L., Gold, R., Hemmer, B., Korn, T., Zipp, F., Hohlfeld, R., Kieseier, B. C., & Wiendl, H. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3283-x · Cited by 17
Tian, D. H., Perera, C. J., Apostolopoulos, V., & Moalem‐Taylor, G. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00168 · Cited by 17
Self-citationLourbopoulos, A. I., Deraos, G., Matsoukas, M., Touloumi, O., Giannakopoulou, A., Kalbacher, H., Grigoriadis, N., Apostolopoulos, V., & Matsoukas, J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.005 · Cited by 17
Self-citationCurrent Therapeutic Options in Pediatric Multiple Sclerosis
Yeh, E. A. (2011) · Current Treatment Options in Neurology · doi:10.1007/s11940-011-0141-x · Cited by 16
Perera, C. J., Lees, J. G., Duffy, S. S., Makker, P. G. S., Fivelman, B., Apostolopoulos, V., & Moalem‐Taylor, G. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.07.004 · Cited by 15
Self-citationYannakakis, M.-P., Simal, C., Tzoupis, H., Rodi, M., Dargahi, N., Prakash, M. D., Mouzaki, Α., Platts, J. A., Apostolopoulos, V., & Tselios, T. V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061215 · Cited by 15
Self-citationIL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine
Naderi, S., Hejazi, Z., Shajarian, M., Alsahebfosoul, F., Etemadifar, M., & Sedaghat, N. (2016) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2016.1195746 · Cited by 14
Kang, Y., Sun, Y., Zhang, J., Gao, W., Kang, J., Wang, Y., Wang, B., & Xia, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049994 · Cited by 13
Apostolopoulos, V., Deraos, G., Matsoukas, M., Day, S., Stojanovska, L., Tselios, T. V., Androutsou, M., & Matsoukas, J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.029 · Cited by 13
Self-citationChallenges in randomized controlled trials and emerging multiple sclerosis therapeutics
Huang, D. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1560-6 · Cited by 7
Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Sanvito, L., Constantinescu, C. S., & Gran, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798157630 · Cited by 5
Cited by
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
Machado-Santos, J., Saji, E., Tröscher, A. R., Paunovic, M., Liblau, R., Gabriely, G., Bien, C. G., Bauer, J., & Lassmann, H. (2018) · Brain · doi:10.1093/brain/awy151 · Cited by 548
A Global Review on Short Peptides: Frontiers and Perspectives
Apostolopoulos, V., Bojarska, J., Chai, T.-T., Elnagdy, S., Kaczmarek, K., Matsoukas, J., New, R., Parang, K., Lopez, O. P., Parhiz, H., et al. (2021) · Molecules · doi:10.3390/molecules26020430 · Cited by 421
Self-citationErickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
Metadata
- Authors
- Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-07
- Volume
- 7
- Issue
- 7
- Pages
- 78
- ISSN
- 2076-3425 (ISSN-L)
- OpenAlex
- W2732823864
- Cited by
- 285
- References
- 164
- FWCI
- 20.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.